Revolutionary Trends in Adolescent Stimulant Use

A groundbreaking analysis from JAMA Network Open has revealed a significant shift in stimulant use among U.S. adolescents. Between 2005 and 2023, the medical use of prescription stimulants for ADHD rose slightly, while nonmedical use plummeted to its lowest levels ever recorded. High school seniors, who once led in misuse, showed the most remarkable decline. The study indicates long-term prescribed users are less likely to misuse stimulants, soothing concerns about potential diversion. However, experts caution the need for continual monitoring as prescribing patterns evolve.

Inhaled Insulin Innovation: A Game Changer for Type 1 Diabetes

On August 6, 2025, MannKind Corporation announced it has submitted a supplemental Biologics License Application to the FDA for its revolutionary inhaled insulin, Afrezza, tailored for children with type 1 diabetes. This pivotal filing was grounded in the promising findings of the INHALE-1 study, which demonstrated that inhaled insulin performs almost identically to injected rapid-acting insulin. Lead researcher Dr. Michael Haller emphasized that excluding data from non-compliant patients highlighted the efficacy of the new inhaled method.

School Asthma Management: A Call to Action!

With asthma being a leading cause of absenteeism among U.S. students, it’s crucial for families and schools to collaborate closely to manage this chronic condition effectively. Experts report that nearly 1 in 10 students are affected, with heightened risks for low-income populations. As schools reopen, ensuring students have the necessary medications, recognizing symptoms, and maintaining clear communication with school staff can significantly reduce asthma flare-ups. Practical strategies like pacing during exercise and preemptive allergy medication can empower kids to thrive in the classroom.

FDA Approvals: New Treatments for Pediatric Patients

In more exciting news, the FDA granted approval for tocilizumab-anoh (Avtozma) for treating cytokine release syndrome (CRS) in children aged 2 and older, expanding its prior uses. This innovative biosimilar is expected to be available by the end of August 2025. Additionally, the FDA approved fremanezumab-vfrm (Ajovy) for migraine prevention in kids aged 6 and up, marking a significant leap in pediatric migraine treatments. Both approvals were backed by solid clinical trial data, showcasing their safety and efficacy.

Stay Informed and Empowered!

Stay on top of these crucial developments in pediatric health! Subscribe to our updates to receive the latest news, clinical insights, and vital information straight to your inbox.